Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors

Topics:
Healthcare Services
Tags:
Millennium Pharmaceuticals Inc.,
VELCADE
Source:
Millennium Pharmaceuticals

FREE Registration is required

Overview: In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor activity were observed with VELCADE as both a single agent and in combination with other therapies. VELCADE Studied as a Single Agent in Non-Hodgkin's Lymphoma Preliminary data from two phase II studies of VELCADE as a single agent for the treatment of indolent and aggressive NHL were also presented.

(Is this item miscategorized? Does it need more tags? Let us know.)

Format: HTML | Date: Jun 2003 | Pages: 3

Top results from Healthcare Services

Resource Center Protect your patient data and your budget at the same time
White Paper New HIPPA Regulations Require Quick Action By Group Health Plans
White Paper A Common Language Architecture for Health Care
White Paper A Digital Imaging Transformation in Radiology Departments
White Paper Alternative Health Care Models

» View all Healthcare Services listings

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Returning users: Log In Here!

Already registered on BNET, TechRepublic, or ZDNet? Simply log in.

Free Membership: Sign Up Now!

Sign up for a free membership today and get instant and unlimited access to one of the largest databases of white papers, webcasts, and casestudies anywhere. Your FREE membership allows you to:

  • Download an unlimited amount of content, including classic and current white papers, case studies, webcasts and more
  • Track content on your chosen topics of interest
  • Receive targeted email alerts when your favorite content is added
  • Save content for future reading
  • Receive our member newsletter

When you register to access this directory, you become a member of BNET. In addition, you allow us to share your information with companies that produce products or services featured in the library--so that such companies may contact you with information and offers regarding their products and services. This enables us to keep the library a free service. As a directory registrant, you will receive a complimentary subscription to the BNET member newsletter, The BNET Report. You can unsubscribe from this newsletter at any time. By clicking the Sign up button, you indicate that you agree to our Terms and Conditions and have read and understand our Privacy Policy (updated).